tiprankstipranks
Advertisement
Advertisement

XENE Stock Latest News

Xenon to Spotlight Azetukalner Phase 3 and Mechanistic Data at EEC 2026
Company AnnouncementsXenon to Spotlight Azetukalner Phase 3 and Mechanistic Data at EEC 2026
3h ago
XENE
H.C. Wainwright says Biohaven license agreement buys time, ‘not a solution’
PremiumThe Fly
H.C. Wainwright says Biohaven license agreement buys time, ‘not a solution’
5h ago
BHVN
XENE
Xenon Pharmaceuticals’ Earnings Call Signals Pivotal NDA
PremiumCompany Announcements
Xenon Pharmaceuticals’ Earnings Call Signals Pivotal NDA
4d ago
XENE
Xenon Therapeutics: Buy Rating Reiterated as AZK Progress and Strong Cash Position Support Compelling Risk-Reward; Price Target Maintained at $78
PremiumRatings
Xenon Therapeutics: Buy Rating Reiterated as AZK Progress and Strong Cash Position Support Compelling Risk-Reward; Price Target Maintained at $78
19d ago
XENE
Xenon Pharmaceuticals price target lowered to $81 from $82 at RBC Capital
PremiumThe Fly
Xenon Pharmaceuticals price target lowered to $81 from $82 at RBC Capital
19d ago
XENE
Xenon advances azetukalner toward planned U.S. NDA filing
PremiumCompany AnnouncementsXenon advances azetukalner toward planned U.S. NDA filing
20d ago
8K
XENE
Xenon Pharmaceuticals reports Q2 EPS ($1.11), consensus ($1.16)
Premium
The Fly
Xenon Pharmaceuticals reports Q2 EPS ($1.11), consensus ($1.16)
20d ago
XENE
XENE Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
XENE Upcoming Earnings Report: What to Expect?
23d ago
XENE
Biohaven downgraded to Underperform from Neutral at BofA
PremiumThe Fly
Biohaven downgraded to Underperform from Neutral at BofA
2M ago
BHVN
XENE
Xenon Shareholders Approve Directors, Pay and Incentive Plan
PremiumCompany Announcements
Xenon Shareholders Approve Directors, Pay and Incentive Plan
3M ago
8K
XENE
Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan
3M ago
XENE
Xenon Pharmaceuticals Signals Strong Momentum In Earnings
PremiumCompany Announcements
Xenon Pharmaceuticals Signals Strong Momentum In Earnings
3M ago
XENE
Xenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan
PremiumThe FlyXenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan
4M ago
XENE
Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo
Premium
The Fly
Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo
4M ago
PRAX
XENE
Xenon Pharmaceuticals Maps Path After Standout XTOL-2
Premium
Company Announcements
Xenon Pharmaceuticals Maps Path After Standout XTOL-2
4M ago
XENE
Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
PremiumThe Fly
Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
4M ago
XENE
Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
PremiumRatings
Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
4M ago
XENE
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
PremiumCompany Announcements
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
4M ago
8K
XENE
Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20)
PremiumThe Fly
Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20)
4M ago
XENE
XENE Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsXENE Upcoming Earnings Report: What to Expect?
4M ago
XENE
Xenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning
Premium
Ratings
Xenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning
4M ago
XENE
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
Premium
The Fly
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
4M ago
XENE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >